SLC2A1 and acute lymphoblastic leukemia: Importantly, B-ALL cells did not accumulate in vivo and disease did not rapidly progress after Glut1 deletion (Figure 6c) and numbers of Glut1-deficient B-ALL cells were significantly reduced in spleen and bone marrow (Figure 6d), relative to vehicle-treated or control B-ALL.